Harvard Bioscience (NASDAQ:HBIO) Stock Passes Below 200-Day Moving Average - Time to Sell?

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.73 and traded as low as $2.17. Harvard Bioscience shares last traded at $2.24, with a volume of 143,541 shares.

Harvard Bioscience Trading Down 3.6 %

The firm has a 50 day moving average of $2.33 and a 200 day moving average of $2.73. The firm has a market cap of $94.22 million, a PE ratio of -6.27 and a beta of 1.27. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52.

Hedge Funds Weigh In On Harvard Bioscience

Several large investors have recently modified their holdings of HBIO. Barclays PLC boosted its holdings in shares of Harvard Bioscience by 304.4% in the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier's stock worth $157,000 after acquiring an additional 44,150 shares during the period. Geode Capital Management LLC lifted its holdings in Harvard Bioscience by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier's stock worth $2,455,000 after purchasing an additional 19,972 shares in the last quarter. State Street Corp boosted its stake in Harvard Bioscience by 1.1% in the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier's stock worth $1,930,000 after purchasing an additional 7,763 shares during the period. Harvey Partners LLC grew its holdings in Harvard Bioscience by 6.2% during the 3rd quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier's stock valued at $7,303,000 after buying an additional 157,500 shares in the last quarter. Finally, Corsair Capital Management L.P. bought a new stake in shares of Harvard Bioscience during the third quarter valued at about $63,000. Hedge funds and other institutional investors own 80.87% of the company's stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.